1 Market
1.1 Market Outlook
1.1.1 Market Overview
1.1.2 Product Definition
1.1.3 Inclusion and Exclusion Criteria
1.1.4 Key Findings
1.2 Industry Outlook
1.2.1 Key Trends
1.2.1.1 Significant Number of Collaborations among Market Players
1.2.1.2 Increasing Investment for Expansion of Nucleic Acid Therapeutics CDMO Manufacturing Units
1.2.1.3 CDMOs Shifting their Business Strategy in Response to a Changing Environment
1.2.2 Opportunity Assessment
1.2.3 Patent Analysis
1.2.3.1 Awaited Technological Developments
1.2.3.2 Patent Filing Trend (by Country)
1.2.3.3 Patent Filing Trend (by Year)
1.2.4 Production Capability
1.2.5 Preferred Techniques By CDMO
1.2.5.1 Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
1.2.5.2 Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
1.2.5.3 Preferred Techniques by CDMOs for Nucleic Acid Purification
1.2.6 Factors Considered While Outsourcing To CDMO.
1.2.7 Regulatory Framework
1.3 Impact of COVID-19 on the Nucleic Acid Therapeutics CDMO
1.3.1 Pre-COVID-19 Phase
1.3.2 During COVID-19
1.3.3 Post-COVID-19 Phase
1.3.3.1 Impact on Demand and Supply
1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
1.5 Significant Usage of Nucleic Acid in Therapeutics
1.6 Types of Nucleic Acid Synthesized for Therapeutics
1.6.1 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
1.6.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)
1.6.3 MicroRNAs (miRNAs)
1.6.4 RNA Aptamers and RNA Decoys
1.6.5 Ribozymes
1.6.6 Circular RNAs
1.7 Business Dynamics
1.7.1 Impact Analysis
1.7.2 Business Drivers
1.7.2.1 Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
1.7.2.2 Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
1.7.2.3 Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs
1.7.3 Business Restraints
1.7.3.1 Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
1.7.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutic
1.7.4 Business Opportunities
1.7.4.1 Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses.
1.7.4.2 Pharmaceutical Firms Becoming More Outsourcing-Oriented
2 Nucleic Acid Therapeutics CDMO Market (by Region)
2.1 Europe Nucleic Acid Therapeutics CDMO Market
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.2.1 Impact Analysis
2.1.3 Market Sizing and Forecast
2.1.3.1 Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2 Europe Nucleic Acid Therapeutics CDMO Market (by Country)
2.1.3.2.1 Germany
2.1.3.2.1.1 Germany Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.2 U.K.
2.1.3.2.2.1 U.K. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.3 France
2.1.3.2.3.1 France Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.4 Spain
2.1.3.2.4.1 Spain Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.5 Italy
2.1.3.2.5.1 Italy Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
2.1.3.2.6 Rest-of-Europe
2.1.3.2.6.1 Rest-of-Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
3 Markets - Competitive Benchmarking & Company Profiles
3.1 Competitive Benchmarking
3.1.1 Key Strategies and Developments
3.1.1.1 Funding Activities
3.1.1.2 New Offerings
3.1.1.3 Mergers and Acquisitions
3.1.1.4 Partnerships and Collaborations
3.1.1.5 Business Expansions
3.1.1.6 Regulatory and Legal Activities
3.1.2 Market Share Analysis
3.1.3 Visual Graphics of Key Companies
3.2 Company Profile
3.2.1 AGC Biologics
3.2.1.1 Company Overview
3.2.1.2 Role of AGC Biologics in the Nucleic Acid Therapeutics CDMO Market
3.2.1.3 Financials
3.2.1.4 Recent Developments
3.2.1.5 Analyst Perspective
3.2.2 BACHEM
3.2.2.1 Company Overview
3.2.2.2 Role of BACHEM in the Nucleic Acid Therapeutics CDMO Market
3.2.2.3 Financials
3.2.2.4 Recent Developments
3.2.2.5 Analyst Perspective
3.2.3 Eurofins Scientific
3.2.3.1 Company Overview
3.2.3.2 Role of Eurofins Scientific in the Nucleic Acid Therapeutics CDMO Market
3.2.3.3 Financials
3.2.3.4 Recent Developments
3.2.3.5 Analyst Perspective
3.2.4 LGC Science Group Holdings Limited
3.2.4.1 Company Overview
3.2.4.2 Role of LGC Science Group Holdings Limited in the Nucleic Acid Therapeutics CDMO Market
3.2.4.3 Recent Developments
3.2.4.4 Analyst Perspective
3.2.5 Merck KGaA
3.2.5.1 Company Overview
3.2.5.2 Role of Merck KGaA in the Nucleic Acid Therapeutics CDMO Market
3.2.5.3 Financials
3.2.5.4 Recent Developments
3.2.5.5 Analyst Perspective
List of Figures
Figure 1: Services Offered by CDMOs
Figure 2: Europe Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Figure 3: Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), % Share, 2022 and 2033
Figure 4: Nucleic Acid Therapeutics CDMO Market (by Region), $Billion, 2022 and 2033
Figure 5: Europe Nucleic Acid Therapeutics CDMO Market: Research Methodology
Figure 6: Primary Research Methodology
Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
Figure 8: Top-Down Approach (Segment-Wise Analysis)
Figure 9: Significant Number of Collaborations among Market Players in Nucleic Acid Therapeutics CDMO Market, 2019-2023
Figure 10: Core CDMO Services
Figure 11: Nucleic Acid Therapeutics CDMO Market Key Trends, Market Shift, 2022-2033
Figure 12: Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Country), January 2018-January 2023
Figure 13: Nucleic Acid Therapeutics CDMO Market, Patent Analysis (by Year), January 2018-December2022
Figure 14: Synthesis Capabilities of Key Companies
Figure 15: Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
Figure 16: Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
Figure 17: Preferred Techniques by CDMOs for Nucleic Acid Purification
Figure 18: Factors considered while outsourcing to CDMO.
Figure 19: Nucleic Acid Therapeutics CDMO Market, Impact Analysis
Figure 20: Significant Increase in Sale of TEGSEDI and WAYLIVRA Drugs in $Million, 2018-2021
Figure 21: Significant Number of Nucleic Acid Drugs Approved by FDA or EMA in Nucleic Acid Therapeutics CDMO Market, 2018-2020
Figure 22: Nucleic Acid Therapeutics CDMO Market Share (by Region), 2022-2033
Figure 23: Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 24: Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 25: Europe Nucleic Acid Therapeutics CDMO Market (by Country), Share (%), 2022 and 2033
Figure 26: Germany Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 27: Germany Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 28: U.K. Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 29: U.K. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 30: France Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 31: France Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 32: Spain Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 33: Spain Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 34: Italy Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 35: Italy Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 36: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
Figure 37: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
Figure 38: Nucleic Acid Therapeutics CDMO Market, Number of Key Developments and Strategies, January 2018-February 2023
Figure 39: Funding Activities, January 2018-February 2023
Figure 40: New Offerings, January 2018-February 2023
Figure 41: Mergers and Acquisitions, January 2018-February 2023
Figure 42: Partnerships and Collaborations, January 2018-February 2023
Figure 43: Business Expansions, January 2018-February 2023
Figure 44: Regulatory and Legal Activities, January 2018-February 2023
Figure 45: Nucleic Acid Therapeutics CDMO Market, Company Revenue Share Analysis, $Billion, 2022
Figure 46: Some of the Active Players in the Nucleic Acid Therapeutics CDMO Market
Figure 47: AGC Biologics: Product Portfolio
Figure 48: AGC Biologics: Overall Financials, $Million, 2019-2021
Figure 49: AGC Biologics: Segment Revenues, $Million, 2019-2021
Figure 50: AGC Biologics: Net Revenue (by Region), $Million, 2020-2021
Figure 51: BACHEM: Product Portfolio
Figure 52: BACHEM: Overall Financials, $Million, 2020-2022
Figure 53: BACHEM: Net Revenues (by Segment), $Million, 2020-2022
Figure 54: BACHEM: Net Revenue (by Region), $Million, 2020-2022
Figure 55: BACHEM: R&D Expenditure, $Million, 2020-2022
Figure 56: Eurofins Scientific: Product Portfolio
Figure 57: Eurofins Scientific: Overall Financials, $Million, 2020-2022
Figure 58: Eurofins Scientific: Net Revenue (by Segment), $Million, 2020-2022
Figure 59: Eurofins Scientific: Net Revenue (by Region), $Million, 2020-2022
Figure 60: LGC Science Group Holdings Limited: Product Portfolio
Figure 61: LGC Science Group Holdings Limited: Overall Financials, $Million, 2020-2022
Figure 62: LGC Science Group Holdings Limited: Net Revenue (by Segment), $Million, 2021-2022
Figure 63: LGC Science Group Holdings Limited: Net Revenue (by Region), $Million, 2020-2022
Figure 64: LGC Science Group Holdings Limited: R&D Expenditure, $Million, 2020-2022
Figure 65: Merck KGaA: Product Portfolio
Figure 66: Merck KGaA: Overall Financials, $Million, 2020-2022
Figure 67: Merck KGaA: Net Revenue (by Segment), $Million, 2020-2022
Figure 68: Merck KGaA: Net Revenue (by Region), $Million, 2020-2022
Figure 69: Merck KGaA: R&D Expenditure, $Million, 2020-2022
List of Tables
Table 1: Nucleic Acid Therapeutics CDMO Market, Key Developments Analysis, January 2018-February 2023
Table 2: Key Questions Answered in the Report
Table 3: Some of the Partnerships and Collaborations in the Nucleic Acid Therapeutics CDMO Market
Table 4: Nucleic Acid Therapeutics CDMO Market, Key Investment
Table 5: Regulatory Organization: Nucleic Acid Therapeutics CDMO Market
Table 6: Nucleic Acid Drugs Approved by FDA or EMA, 2018-2021
Table 7: Advancements in Manufacturing Units of CDMO
Table 8: Europe Nucleic Acid Therapeutic CDMO Market, Impact Analysis
